2023 World Conference on Lung Cancer (Posters)-P1.13. The LuCID Study: Detection of Lung Cancer Breath Biomarkers via Breath Biopsy in a Multi-Centre Trial

P1.13. The LuCID Study: Detection of Lung Cancer Breath Biomarkers via Breath Biopsy in a Multi-Centre Trial - PDF(Slides)

Back to course

Pdf Summary

The LuCID study, conducted by Owlstone Medical Ltd., aims to evaluate the potential of breath biomarkers for the early detection of lung cancer. The study analyzed the breath of 1844 individuals suspected of having lung cancer using two different analytical methods. The results showed that 11 breath biomarkers were significantly different between cases and controls, but these differences did not remain significant after correcting for multiple testing. In a multivariate analysis, the performance of these breath biomarkers did not exceed that of an established epidemiological risk prediction model. The study concluded that endogenously produced breath biomarkers have limited diagnostic potential for the early detection of lung cancer in the relevant clinical population. Targeted approaches that amplify the volatile biomarkers associated with metabolic pathways altered in lung cancer may be needed for the development of a breath-based screening test. The study also mentioned ongoing research focused on exploiting a specific metabolic pathway for the detection of lung cancer using an exogenous volatile organic compound (VOC) probe. Overall, the LuCID study provides insights into the current limitations and challenges of breath analysis for lung cancer detection and highlights the need for further research in this area.

Asset Subtitle

Marc Schee

Meta Tag

Speaker Marc Schee

Topic Screening & Early Detection: Biomarkers/Imaging Technology

Keywords

LuCID study

Owlstone Medical Ltd.

breath biomarkers

lung cancer

early detection

analytical methods

multivariate analysis

diagnostic potential

metabolic pathways

volatile organic compound (VOC) probe